Hormones

Hormones

 

 

Finasteride,98319-26-7
Finasteride
Finasteride,98319-26-7
Product Name
Finasteride
Synonyms
Propecia 
Systematic Name
4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)- 
CAS No.
98319-26-7
Molecular Formula 
C23H36N2O2
Molecular Weight
372.5494
Assay
USP37/US-DMF available
Certificate of analysis
Finasteride,98319-26-7
Intermediates
N-t-Butyl-3-Oxo-4-Aza-5-Androsten-17β-Carboxamide
Methyl 3-Oxo-4-Androsten-17β-Carboxylate
Items
Specification
Test result
Appearance
White or almost white crystalline powder
Complies
Identification
Should comply with the requirements
Complies
Loss on drying
≤0.5%
0.21%
Specific rotation
+12 to +14°
+13.66°
Related substances
Impurity A :Max 0.3%
Impurity B :Max 0.3%
Impurity C :Max 0.3%
Other single impurity: Max 0.1%
Total impurities: 0.6%
0.22%
0.05%
0.04%
0.09%
0.45%
Assay
98.0%~102.0%(on the dried basis)
99.42%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Packing
Finasteride,98319-26-7
Packing 1
10g
Packing 2
1kg
   
   
   
Bulk request
sales@lanospharma.com
Related Hormones
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Finasteride,98319-26-7).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.